AIHTA - Publications - Search - Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC)

Wolf, S. (2021): Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 61.

[thumbnail of Oncology Fact Sheet Nr.61.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
104kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WF Respiratory system
Language:English
Series Name:Oncology Fact Sheet Nr. 61
Deposited on:15 Oct 2021 15:13
Last Modified:15 Oct 2021 15:50

Repository Staff Only: item control page